that manifestations of HE are completely reversible. However, more recent research in liver transplant patients and in patients with recurrent HE episodes showed that cognitive abnormalities may persist. 16, 17 Rarely, persistent HE may present with irreversible (extra-)pyramidal signs.
Epidemiology
Incidence and prevalence of HE are highly related to the severity and type of the liver disease.
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In CLD, the overall prevalence of fully symptomatic HE at the time of diagnosis of cirrhosis is 10 to 14% [21] [22] [23] and 16 to 21% in the subgroup of patients with decompensated cirrhosis. 5, 24 In 30 to 40% of patients with cirrhosis, HE will develop at some point during the clinical course. 25 In 5 to 25% of patients, the first episode of fully symptomatic HE develops within 5 years after the diagnosis of cirrhosis, depending on the presence of risk factors, such as subclinical HE, infections, variceal bleeding, or ascites. [26] [27] [28] [29] [30] Patients with a previous episode of HE have a cumulative risk of recurrence of 40% within 1 year. 31 Recently, a large, prospective study assessing the natural history of patients admitted for acute decompensation (AD) of liver cirrhosis showed that the incidence of HE in these patients was 34%. 32 In the subgroup of patients with acute-on-chronic liver failure (ACLF), which was found to be a distinct entity from AD and associated with (multi-)organ failure and high short-term mortality, survival was significantly lower in patients with HE as compared with those without HE. This indicates that the presence of HE significantly adds to the risk of death, independently from other organ failures.
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Acute liver failure (ALF) is characterized by severe acute liver injury with impaired synthetic function (international normalized ratio > 1.5) and the development of HE in a patient without prior liver disease. 34 Unlike CLD, ALF can lead to cerebral edema with increased intracranial pressure (ICP), potentially leading to cerebral herniation and death. 35, 36 Over the last decades, a considerable decline in the incidence of cerebral edema in ALF has been observed and is now seen in less than 25% of patients. 16, 17 This may be due to the implementation of emergency liver transplantation as well as practical improvements in critical care management. When present, however, cerebral edema in ALF is still associated with very poor survival.
37-39

Classification
The disease classification and grading are of high importance, as it guides patients' treatment strategies. Although subclinical stages can often be managed in an outpatient setting, clinically apparent HE requires hospital admission, imminent treatment, and intensive care management in higher grades.
Considering the intra-and inter-individual variability of symptoms, reliable diagnostic tools to define and grade HE are of high importance. To optimize the diagnostic accuracy, the current European Association for the Study of the Liver (EASL)/American Association for the Study of Liver Diseases (AASLD) guideline 1 implemented a multiaxial classification system, categorizing HE into (1) the underlying disease (type A: ALF, type B: portosystemic bypass or shunting, type C: cirrhosis), (2) the severity of the manifestations, (3) time course (episodic, recurrent, persistent), and (4) the existence of precipitating factors (►Fig. 1). An additional category has been proposed according to the presence of ACLF, 33 as it is a distinct entity from CLD and ALF in terms of 
Diagnosis
The diagnosis of OHE is primarily based on clinical signs and context. 1 As described previously, WHC is the gold standard to diagnose and grade the severity of OHE. 1,9 A limitation of the WHC is that it is a subjective tool, resulting in interobserver variability. In contrast, the presence of disorientation and asterixis has been found to have a good inter-rater reliability and are therefore considered key symptoms of OHE. 41 The Glasgow Coma Scale is widely implemented for patients with a markedly altered level of consciousness and supplies an accurate description of the disease severity. Blood ammonia levels may be useful as the absence of hyperammonemia makes the diagnosis of OHE unlikely. In contrast, a high level of blood ammonia alone in patients with CLD has no diagnostic or prognostic value. 42 Therefore, in clinical practice ammonia measurements in CLD remain controversial. In ALF, however, there is a good correlation between blood ammonia and disease severity and prognosis. 43 In patients with ALF and brain edema, it has been shown that persistent elevation of arterial ammonia (>124 µmol/L) following initial therapeutic interventions is associated with an increased risk of intracranial hypertension. [44] [45] [46] Ammonia measurements comprise some logistic obstacles that should be taken into consideration. First of all, arterial blood should be preferred over venous blood as it gives more reliable results. 47, 48 However, this advantage is limited and is therefore considered acceptable.
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When venous blood is used, it should preferably be drawn when the patient is fasting, stored and transported on ice, and analyzed immediately. Even when clinical signs are clear, it does not absolve from the necessity to search for precipitating events on the one hand and to be alert on alternative causes for an altered mental state on the other hand, as both require either additional or alternative treatments. Especially in (end-stage) CLD, OHE is considered a "diagnosis of exclusion," as this patient population is prone to other causes of mental state abnormalities, such as several types of metabolic encephalopathy as well as nonmetabolic causes (i.e., alcohol abuse, drug use, psychiatric disorders, cerebrovascular disease). Therefore, laboratory or radiological diagnostics may be needed to exclude these alternative causes. Cerebral imaging is recommended in case of nonspecific clinical presentation or when cerebrovascular disease is suspected. However, it does not add any diagnostic or grading information.
1 Moreover, other complications of advanced liver disease, such as infections and hyponatremia, may either lead to mental states mimicking OHE (i.e., delirium) or be the precipitating factor for HE. All of the aforementioned factors may, of course, coexist with OHE, which makes the diagnostic process a complex one.
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Based on the most recent guideline and literature, we have summarized practice recommendations for diagnosing OHE in ►Table 2.
Pathogenesis
Although the complex pathogenesis of HE remains not fully elucidated, hyperammonemia is still thought to be the key mediator. However, other distinct pathophysiological mechanisms are involved, including impaired energy metabolism, 47 oxidative stress, 48 systemic inflammation, 49,51 cerebral hemodynamic dysregulation, and impaired blood-brain barrier (BBB) permeability. 52 Especially the role of inflammation has gained more and more importance in both acute and CLD in the past decades. Moreover, there appears to be a synergistic relationship between hyperammonemia and inflammation in the progression of HE in CLD, ACLF, and ALF. [52] [53] [54] [55] [56] Another important factor in the pathogenesis of HE is an altered cerebral blood flow (CBF), which seems to be directly linked to hyperammonemia and inflammation. 57, 58 Therefore, hyperammonemia, systemic inflammation, and CBF seem to be critical in the current paradigm for the pathophysiology of HE and will be discussed in further detail later.
Hyperammonemia and Its Consequences
Ammonia is a nitrogen-containing compound that is neurotoxic at elevated concentrations. The intestine is the major supplier of plasma ammonia levels (responsible for $50% of the plasma load). Intestinal ammonia is produced by bacterial metabolism of urea from consumed proteins and by glutamine deamination by glutaminase. 59 Another main source of ammonia is its production by the kidney, which is responsible for approximately 40% of plasma ammonia levels. Ammonia is mainly metabolized by the periportal hepatocytes through the urea cycle and is subsequently cleared by the kidneys and (to a lesser extent) by the muscles. 60 Liver dysfunction is therefore associated with impaired detoxification of ammonia and portal hypertension leads to shunting of ammonia-containing blood to the systemic circulation. Ammonia crosses the BBB and is metabolized by astrocytes by converting glutamate and ammonia into glutamine by the enzyme glutamine synthetase. At elevated plasma ammonia concentrations, accumulation of glutamine creates an osmotic gradient resulting in astrocyte swelling and astrocyte dysfunction.
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Another ammonia-related contributor to neurotoxicity in HE is the activation of N-methyl-D-aspartate (NMDA) receptors by astrocytes stimulated by ammonia. This results in a decrease in antioxidant enzyme activity and increases the production of reactive oxygen species (ROS). 62, 63 In addition, mitochondrial dysfunction caused by exposure to high amounts of glutamine may lead to enhanced oxidative stress in astrocytes. 64 Also systemic inflammation, a common and significant feature in HE, contributes to the generation of oxidative stress by neutrophil activation and enhanced ROS production. 52 An excess of these oxidative agents may lead to oxidization of RNA, resulting in impaired protein synthesis and 
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Other actions of ammonia on the brain include the effects on excitatory and inhibitory neurotransmission, inhibition of glucose oxidation, and stimulation of glycolysis.
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Systemic Inflammation Hypothesis
Although there is a large amount of evidence showing that ammonia plays a key role in the pathogenesis of HE, the correlation between blood ammonia levels and HE severity in CLD is poor, 49, 74 meaning that other mechanisms are involved. In cirrhotic patients, infection is a well-known precipitating factor for HE. The presence of infections, especially pneumonia and sepsis, significantly impact on the mortality risk in these patients. 75 In addition, multiple studies revealed that an elevated blood level of the proinflammatory cytokine tumor necrosis factor (TNF)-α positively correlates with the severity of HE. 49, 76, 77 Also in ALF, the presence of a systemic inflammatory response syndrome (SIRS) is involved in the progression of HE and therefore negatively impacts on prognosis. 78, 79 In ACLF, sepsis was found to be an important precipitating factor for HE in previously stable CLD. 80 Based on these observations, it was hypothesized that systemic inflammation is directly involved in the pathogenesis of HE. It has indeed been shown that the peripheral immune system communicates with the brain in the setting of systemic inflammation in liver disease, although the underlying mechanisms are not fully understood. During infection, the systemic inflammatory response leads to a cytokine storm and release of inflammatory modulators that may impact on the permeability and signaling pathways through the BBB. 81 This may in turn lead to microglia activation and local production of proinflammatory cytokines (i.e., TNF-α, interleukin (IL)-1B, and IL-6), a phenomenon referred to as "neuroinflammation." 78 This has especially been shown in advanced stages of HE in ALF, while the degree of neuroinflammation in CLD seems less pronounced and relies on the characteristic of the precipitating factor. 82 Multiple studies have shown that neuroinflammation can lead to neuronal cell death.
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Endotoxemia secondary to bacterial infections plays an important role in the development of a systemic inflammatory response and thus in the development of neuroinflammation in liver disease. Besides infections, endotoxemia can result from intestinal bacterial translocation due to impairment of the intestinal barrier integrity in cirrhosis and directly from the liver dysfunction. 85, 86 Many studies have
shown that bacterial antigens, such as lipopolysaccharide (LPS), are involved in the development of HE. In several ALF animal models, LPS administration has been shown to increase BBB permeability and lead to coma. 87 Also in a CLD model, as induced by bile duct ligation (BDL) in rats, the administration of LPS was found to induce coma. 56 Moreover, LPS administration in BDL rats has been found to exacerbate brain edema through a synergistic effect of hyperammonemia and endotoxemia.
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Synergy between Hyperammonemia and Systemic Inflammation
Data of recent animal studies suggest that hyperammonemia and systemic inflammation are nonisolated pathomechanisms, but act synergistically in producing the clinical manifestations of HE in both acute and CLD. 52, 53, 55, 56 In a CLD rat model, for example, it was shown that administration of LPS resulted in hyperammonemia, brain swelling, and coma.
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Moreover, another study showed that a reduction in blood ammonia level protected the brain from a subsequent injection with LPS, suggesting that ammonia makes the brain more susceptible for a secondary inflammatory hit. 56 This was confirmed in a human study, in which significant deterioration in neuropsychometric tests was shown following induced hyperammonemia during the inflammatory state, but not after resolution of the infection. 55 Interestingly, administration of ammonia to healthy rats activates the microglial cells, which modulate neuroinflammation. 88 The exact mechanism behind this synergistic relationship is still subject of research, but it potentially provides interesting therapeutic targets for HE, such as endotoxin receptors, which will be discussed in the next section.
Brain Edema and the Role of Cerebral Hemodynamics
Altered CBF is a crucial factor in the pathogenesis of HE. While CLD is known to be associated with progressive reduction in CBF (i.e., cerebral oligemia), ALF is characterized by significant increases in CBF (i.e., cerebral hyperemia).
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Cerebral hyperemia may lead to an increase in brain blood volume and promotes the movement of water through the BBB and is therefore relevant to the pathogenesis of ICP. Multiple mechanisms are involved in inducing alterations in cerebral hemodynamics in ALF, among which inflammation and hyperammonemia, acting synergistically, seem once again to be important mediators.
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Unlike ALF, mild brain edema has been shown in patients with CLD and HE using advanced magnetic resonance imaging techniques. 89 Nevertheless, lower grade edema appeared to be a significant feature in these patients, as improvement of HE was found to be associated with a decrease in brain edema. 90 In ACLF, severity of brain edema and intracranial hypertension have not been studied extensively yet, but a significant increase in ICP has been previously described in small studies. 53,91 A more recent study reports a relatively low incidence of highgrade cerebral edema in ACLF patients of approximately 5%.
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In summary, the current paradigm for the pathogenesis of HE in both acute and chronic liver disease involves the interaction between hyperammonemia, systemic inflammation, and CBF and these pathomechanisms are therefore clear therapeutic targets for HE.
Treatment General Management
The management of patients with HE has two primary goals: (1) to prevent HE-related complications (e.g., brain herniation, aspiration, asphyxia) and (2) to restore patients' individual cognitive function and consciousness. All patients with OHE must be evaluated for intensive care monitoring and treatment. Although patients with preserved synthetic liver function and mild to moderate HE (i.e., WHC grades 1-2) can be safely managed on the normal ward, HE in association with ALF or ACLF is an indication for transfer to ICU to protect the airway, provide full organ support including mechanical ventilation, vasopressor support, and renal replacement therapy.
The management strategy depends on the underlying liver disease. In ALF, HE development is a direct consequence of the acute deterioration of liver function and subsequent hyperammonemia and inflammation, which may result in cerebral edema and increase in ICP. 87, 93 Therefore, treatment strategies in ALF focus on reducing the ICP and identifying patients eligible for high urgency liver transplantation. This is in contrast to ACLF, in which HE is dominated by a proinflammatory reaction and less strongly associated with hyperammonemia. Moreover, in ACLF, HE is triggered in more than 60% of patients by precipitating events such as alcohol binge, infection, electrolyte disbalance, gastrointestinal bleeding, and treatment with diuretic agents. This is in contrast to the widespread belief that protein restriction hastens the recovery after HE. Long-term energy and protein restriction must be avoided, also in obese patients with cirrhosis, as it leads to protein depletion and exacerbation of HE. 93 In this situation, endogenous amino acids are utilized to maintain the blood sugar levels. This leads to protein break down and production of ammonia.
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In stressful situations such as intensive care stays, the energy and protein requirement might be even higher.
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Hyperammonemia is considered the main cause of reduced levels of branched chain amino acids (BCAAs). 97 Its oral supplementation has been reported to enhance ammonia detoxification, 98, 99 to stimulate the secretion of hepatocyte growth factor 100 which stimulates liver regeneration, to induce muscle protein synthesis 101 and insulin secretion.
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A recent Cochrane meta-analysis confirmed the clinical efficacy on the development of HE by analyzing 16 studies, although the survival endpoint was not met. 97 However, BCAA supplementation is not effective in patients with OHE.
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Patient with liver cirrhosis, notably with alcoholic liver cirrhosis, are prone to be thiamine deficient 93 and are therefore at risk of developing a Wernicke's encephalopathy. Although there are disease-specific symptoms such as nystagmus and ptosis, clinical presentation of Wernicke's encephalopathy may overlap with HE (e.g., ataxia, confusion, memory loss), making the diagnostic process challenging. As thiamine substitution is cheap and safe, thiamine should be given in all patients with HE associated with alcoholic liver disease.
Current Specific Treatments
Therapies Targeting the Gut
Nonabsorbable disaccharides, notably lactulose, is traditionally used as the initial treatment in HE associated with CLD. Lactulose has a restoring effect on the intestinal dysbiosis, as it reduces the amount of ammonia-producing bacteria. In of use, and the small spectrum of side effects still speak for its widespread use as a first-line treatment in cirrhosisassociated HE. Initially, lactulose is given to achieve two to three loose bowel movements daily. The dose can be increased if there is no treatment response, or alternatively administered as enema. 94 However, at higher doses, side effects such as hyponatremia, dehydration, meteorism, and skin irritation occur more frequently and may limit its applicability. Polyethylene glycol, which is commonly used as laxative, might be an alternative to lactulose, as shown in a small study with 50 patients. Administration of polyethylene glycol resulted in a significantly quicker resolution of the HE episode. 105 However, further validation is needed before polyethylene glycol could be implemented as a first-line treatment. In ALF, the evidence for the efficacy of lactulose is limited and the oral administration may cause gastrointestinal side effects such as bowel distension and worsening of paralytic ileus, which ultimately jeopardizes liver transplantation.
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If necessary, rectal administration should be preferred over the oral approach, as it less likely causes treatment-related complications.
Rifaximin (550 mg BD) is a nonabsorbable antibiotic agent, which inhibits bacterial RNA synthesis by binding to the DNAdependent RNA polymerase. It targets the intestinal dysbiosis, the bacterial translocation, and reduces the production of neurotoxin (ammonia) and the amount of circulating endotoxins. 107 In most European and North American countries, rifaximin is approved and tested to prevent the development of HE episodes [108] [109] [110] the use of rifaximin for the acute HE bout in association with ACLF is limited to treatment of nonresponders.
Rifaximin was not evaluated for HE associated with ALF and can therefore not be recommended in this setting.
Ammonia Targeting Therapies
L-Ornithine L-aspartate (LOLA) is known to lower ammonia levels by interacting with the glutamine synthetase and urea cycle enzyme system. 112 While the oral effect especially in the acute situation is questionable, the intravenous administration (25-40 g/day, max 5 g/hour) was shown to reduce ammonia levels and improve the performance of psychometric tests. 112 This was confirmed by a published meta-analysis.
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However, a recently released Cochrane meta-analysis emphasized that the quality of evidence is poor. Further trials are required 114 and its use is restricted to countries in which it is approved for the treatment of HE. The potential ammonia regeneration from glutamine breakdown may lead to a rebound effect and a certain number of nonresponder.
115
In ALF, LOLA was not effective in improving the HE severity, 116 although its ammonia lowering effect had been shown previously.
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Albumin
Albumin plays a prominent role among all plasma proteins. Its effect goes far beyond the maintenance of the systemic oncotic pressure. It comprises numerous additional functions, including detoxification, modulating inflammation, and stabilizing endothelial function. 118 However, currently there are no credible data showing a true benefit in HE, which adds to the plasma expanding effect of albumin, 119 although a survival benefit in the setting of cirrhosis-associated HE has been shown. 120 HE is therefore not an indication for albumin administration. However, albumin is a crucial component in most extracorporeal liver-assist devices, as discussed later, and might through this channel gain importance in the treatment of HE.
Management of Intracranial Hypertension Measurement and Monitoring
Under normal conditions, the ICP approximately equals the central venous pressure. However, in the setting of intracranial hypertension, the ICP increases above 20 mm Hg. Increased ICP can reduce the cerebral perfusion pressure (CPP), thereby increasing the risk of ischemic brain damage on the one hand and herniation of the brain on the other hand. 121 As previously discussed, intracranial hypertension and cerebral edema are more prominent in ALF than in ACLF. Therefore, management strategies are primarily developed for patients with ALF. Nevertheless, its principals do also apply to patients with ACLF.
If there is evidence of intracranial hypertension, adequate monitoring is essential. Given the fact that patients with liver failure have a coagulopathy and are therefore at risk of bleeding complications, invasive measurement of intracranial pressure should be carefully considered. There is no agreement on the localization of the pressure probe, ranging from epidural over subdural and intraparenchymal to intraventricular. 121 Although the epidural approach bears the lowest risk for complications, the intraparenchymal and intraventricular probes do provide the most accurate results. 121 Ultimately, the access path strongly depends on the confidence of the neurosurgeon and individual patient factors such as the severity of coagulopathy. Unfortunately, there are no randomized controlled trials proving the general efficacy of this measure. Some data from uncontrolled trials suggest that invasive pressure measurement might reduce the frequency of HE-related endpoints with a low risk of complications. 122, 123 In a case series of 37 patients with ALF and HE grade 4, intraparenchymal probes were inserted after sufficient substitution with recombinant factor VIIa and desmopressin, elevating the platelet count to greater than 50,000/mm 3 and the fibrinogen level to greater than 100 mg/dL. 122 In this study, one patient developed an intracranial bleed but required evacuation of the hematoma. Four patients died due to brain herniation and thus uncontrolled intracranial hypertension. Although this study has several limitations, of which the missing control group is certainly the most important one, it shows that under certain conditions invasive ICP measurement is feasible with an acceptable risk of complications. However, data from other studies underline the conflicting discussion regarding this measure.
A large case-control study in 629 patients with ALF and HE grade 3/4 matched 140 patients with invasive ICP measurements with 489 noninvasively monitored patients. Bleeding complications were rare (4/56, 7%). Nevertheless, in nonparacetamol-induced ALF, invasive ICP measurement was associated with an increased risk of death with a hazard ratio of 3. 124 In this study, the cause of inferiority of invasive ICP monitoring could not be clarified. It might be related to a more aggressive ICP treatment or selection of sicker patients. 124, 125 In conclusion, the benefit of invasive ICP monitoring needs to be proven weighing up the risk of bleeding versus benefit. The high costs and the potential complications of invasive ICP management emphasize the need for the development of noninvasive assessment strategies. There are numerous studies evaluating transcranial Doppler ultrasound techniques to assess the intracranial pressure. However, only a few reported the correlation with invasive methods and showed a wide range of sensitivity (25-100%) 126,127 and specificity (69-99%). 128, 129 In addition, the reliability of this method is highly investigator dependent and data in adult liver disease patients still do not exist.
Treatment of Increased Intracranial Hypertension
Treatment strategies for intracranial hypertension focus on the reduction of the cerebral edema and the maintenance of the CPP. Therapies of intracranial hypertension correspond to the principals of the general neurological and neurointensive care management. Intravenous sedation with barbiturates, an elevated head position, and controlled sodium levels (aim 145-150 mmol/L) should be achieved. If necessary, continuous hypertonic saline (►Fig. 2b, ►Table 4).
Results from a systematic review published in 2010 suggested that hypothermia in ALF with intracranial hypertension is effective, feasible, and safe in the treatment of uncontrolled intracranial hypertension. 123 However, a recently published randomized controlled trial investigated 46 patients with ALF, high-grade HE, and intracranial pressure measurement into groups with moderate hypothermia (33-34°C) and normothermia. The aim of this study was to evaluate whether hypothermia could prevent sustained ICP elevation. The data did not confirm the benefit of moderate hypothermia in this setting, but the study was thought to be underpowered to detect a difference.
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Extracorporeal Devices
The use of renal replacement, notably continuous venovenous hemofiltration (CVVH), reduces circulating ammonia levels. 134 Therefore, early initiation of CVVH is widely recommended in ALF. 135 Other extracorporeal devices focus on the removal of inflammatory mediators and toxins. Of them, high-volume plasmapheresis has been recently evaluated for the treatment of ALF in comparison with standard of care. 
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A novel extracorporeal assist device, called DIALIVE, combines albumin exchange with endotoxin adsorption. The first study in patients is currently ongoing. This randomized controlled trial is designed as a proof of concept trial in patients with ACLF (NCT03065699).
Overall, there are currently two systems that play a role in the management of HE associated with ALF or ACLF: highvolume plasmapheresis and MARS. Plasma exchange may have its indication in both entities, especially if the circulatory insufficiency is predominating, to stabilize the systemic blood pressure and intracranial perfusion pressure. Patients with HE but without circulatory failure might benefit from MARS, especially as a bridge to transplantation or spontaneous recovery.
Liver Transplantation
HE is traditionally regarded as being fully reversible if treated adequately. Liver transplantation, by restoring liver function, should therefore allow patients to fully recover from their neuropsychological impairment. However, there is evidence suggesting that HE, even after liver transplantation, leaves some cognitive sequelae. 143 A two-component model has been proposed, consisting of a reversible delirium-like state and an irreversible dementia-like state. 143 The delirium-like state relates majorly to the cerebral edema, whereas the dementialike state includes degenerative cerebellar and ganglia alterations. 144 As to whether this significantly impacts the selection of liver transplant candidates is unclear, notably because neuropsychological disorders after liver transplantation are most often multifactorial (e.g., dementia, immunosuppression and depression). HE is therefore perceived as an indication instead of a contraindication for liver transplantation. The role of HE in the organ allocation system for liver transplant candidates depends on the underlying liver disease. In ALF, HE defines the condition. 145, 146 In ACLF, the presence of HE is an independent risk factor for mortality.
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However, liver transplantation is a potentially life-saving intervention in this specific group of patients. 147 HE is not a criterion for prioritization on the waiting list in most countries with MELD score-based organ allocation and standard exceptions for this type of complications do not exist. It is therefore essential to clarify the type of underlying liver disease, as it determines how liver transplantation fits into individual patient management strategies.
Transjugular Intrahepatic Shunt and Portosystemic Shunt Related HE
In patients with refractory HE associated with ACLF, the presence of portosystemic shunts should be excluded. If large shunts are present, their occlusion may improve HE especially if the liver function is preserved (MELD 11 or below).
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After transjugular intrahepatic shunt (TIPS) insertion, HE may occur in up to 50% of patients and is associated with hyperammonemia, endotoxemia, and cerebral edema. [151] [152] [153] As the efficacy of medical treatment is limited, stent reduction or occlusion remains the gold standard especially in those with refractory or recurrent TIPS-related HE.
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Novel Therapeutic Opportunities
Targeting Ammonia
Ornithine is a component of LOLA and acts by stimulating the glutamine synthetase, which eliminates ammonia to glutamine. LOLA bears the risk of an ammonia rebound phenomenon as glutamine can be recycled to ammonia. 115 New drug formulations combine ornithine with phenylacetate (ornithine phenylacetate) or its prodrug phenylbutyrate, which increases glutamine excretion by binding to phenylacetate.
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Although these treatments were proven to be safe and effective in reducing ammonia, 156, 157 results need to be confirmed in phase 3 study.
Targeting the Intestinal Microbiome
Probiotics, which correct dysbiosis and intestinal bacterial translocation, were tested in prospective trials assessing its capacity to prevent the occurrence of HE bouts. Overall it failed to prove a significant benefit over the standard treatment with lactulose. [158] [159] [160] [161] Besides, a randomized controlled study in acute HE does not exist so that this type of treatment cannot be recommended. Fecal microbiota transplantation is a novel approach to restore dysbiosis 162 and seems to be an attractive target for patients with liver cirrhosis and HE. In fact, its ammonialowering effect has been proven in animal studies 163, 164 and there are currently three human studies actively recruiting patients (NCT03014505, NCT02862249) or completed recruitment (NCT02636647). However, in the setting of acute HE and intensive care, treatment that requires specific resources and logistics might be difficult to implement as first-line therapy.
Targeting (Neuro-)inflammation
There are a few approaches that target altered neuro-(inflammatory) pathways. Sildenafil is a phosphodiesterase inhibitor, which improves the function of glutamate-nitric oxide-cGMP (cyclic guanosine monophosphate) pathway and restores extracellular cGMP levels. It has been shown to improve learning abilities in rats with portocaval anastomosis and hyperammonemia. 165 Moreover, a reduction of neuroinflammation along with an improvement of cognitive functions was reported in other studies.
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Indomethacin is a cyclooxygenase inhibitor, which reduces the intracranial pressure in a porcine model and might play a role in humans. 168 Although further studies need to confirm the results, it may be considered in treatment of refractory cases of severe intracranial hypertension in patients with ALF.
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Conclusion
HE is a devastating complication of liver failure and an independent predictor of mortality both in patients with ALF and those with ACLF. Although the mechanisms of HE are still being investigated, ammonia and inflammation are pathogenically important. Therapeutic options for the management of patients with severe HE are limited. Newer strategies based on the better understanding of interorgan metabolism of ammonia are in late stages of development.
With improvements in treatment of HE, it is likely that the survival of patients with ALF and ACLF will improve.
